Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling.

Blood - 8 Nov 2012

Taylor Samuel J, Dagger Samantha A, Thien Christine B F, Wikstrom Matthew E, Langdon Wallace Y

Abstract excerpt

High levels of expression of wild-type Flt3 characterize many hematopoietic proliferative diseases and neoplasms, providing a potential therapeutic target. Using the c-Cbl RING finger mutant mouse as a model of a myeloproliferative disease (MPD) driven by wild-type Flt3, in the present study, we show that treatment with the Flt3 kinase inhibitor AC220 blocks MPD development by targeting Flt3(+) multipotent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzothiazoles
Share to fms-Like Tyrosine Kinase 3

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukocyte Count

Share to Multipotent Stem Cells

Share to Myeloid Cells

Share to Phenylurea Compounds

Share to Proto-Oncogene Proteins c-cbl

Share to Splenomegaly

Source

Identifiers

PMID: 22990016
DOI: 10.1182/blood-2012-06-436675

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling.PMID 22990016Read ↗

Loss of Cbl and Cbl-b ubiquitin ligases abrogates hematopoietic stem cell quiescence and sensitizes leukemic disease to chemotherapySemantic proximity Read ↗

Myeloid leukemia development in c-Cbl RING finger mutant mice is dependent on FLT3 signaling.Semantic proximity Read ↗

Rapidly fatal myeloproliferative disorders in mice with deletion of Casitas B-cell lymphoma (Cbl) and Cbl-b in hematopoietic stem cellsSemantic proximity Read ↗

FLT3-ITD knockin impairs hematopoietic stem cell quiescence/homeostasis, leading to myeloproliferative neoplasm.Semantic proximity Read ↗

Key role of flt3 ligand in regulation of the common lymphoid progenitor but not in maintenance of the hematopoietic stem cell pool.Semantic proximity Read ↗

Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant miceSemantic proximity Read ↗

Loss of c-Cbl E3 ubiquitin ligase activity enhances the development of myeloid leukemia in FLT3-ITD mutant mice.Semantic proximity Read ↗

Myeloproliferation in long-term plasmacytoma-regressor mice.Semantic proximity Read ↗

Inactivating Icmt ameliorates K-RAS–induced myeloproliferative diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.